{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:56Z","timestamp":1786119296854,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/qai.0b013e3181a56f46","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T08:35:47Z","timestamp":1242894947000},"page":"179-184","source":"Crossref","is-referenced-by-count":3,"title":["Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure"],"prefix":"10.1097","volume":"51","author":[{"given":"Francesca","family":"Cossarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Sagnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Salpietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210131","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"OHearn M, et al, and TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-11-20210131","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Cooper D, et al, and TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-11-20210131","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/jmv.20700","article-title":"A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.","volume":"78","author":"Bienvenu","year":"2006","journal-title":"J Med Virol"},{"key":"R4-11-20210131","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/01.aids.0000244212.15951.2b","article-title":"Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.","volume":"20","author":"Bonjoch","year":"2006","journal-title":"AIDS"},{"key":"R5-11-20210131","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R6-11-20210131","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"R7-11-20210131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"R8-11-20210131","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/510531","article-title":"Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.","volume":"195","author":"Deeks","year":"2007","journal-title":"J Infect Dis"},{"key":"R9-11-20210131","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1089\/aid.2006.22.1260","article-title":"Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.","volume":"22","author":"Kitchen","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R10-11-20210131","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.aids.0000174455.01369.ad","article-title":"Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.","volume":"19","author":"Zaccarelli","year":"2005","journal-title":"AIDS"},{"key":"R11-11-20210131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R12-11-20210131","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(98)03201-2","article-title":"Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.","volume":"352","author":"Mocroft","year":"1998","journal-title":"Lancet"},{"key":"R13-11-20210131","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/314623","article-title":"Combination antiretroviral therapy and recent declines in AIDS incidence and mortality.","volume":"179","author":"Vittinghoff","year":"1999","journal-title":"J Infect Dis"},{"key":"R14-11-20210131","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/375781","article-title":"Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.","volume":"188","author":"Lee","year":"2003","journal-title":"J Infect Dis"},{"key":"R15-11-20210131","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/496892","article-title":"Interruption of treatment with individual drug classes in adults with multidrug-resistant HIV-1 infection.","volume":"192","author":"Deeks","year":"2005","journal-title":"J Infect Dis"},{"key":"R16-11-20210131","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).","volume":"20","author":"Castagna","year":"2006","journal-title":"AIDS"},{"key":"R17-11-20210131","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJM200102153440702","article-title":"Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.","volume":"344","author":"Deeks","year":"2001","journal-title":"N Engl J Med"},{"key":"R18-11-20210131","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1086\/313520","article-title":"Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy.","volume":"29","author":"Mezzaroma","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R19-11-20210131","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.qai.0000136738.24090.d0","article-title":"Effect of persistent moderate viremia on disease progression during HIV therapy.","volume":"37","author":"Raffanti","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-11-20210131","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcv.2005.02.004","article-title":"Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.","volume":"34","author":"Poveda","year":"2005","journal-title":"J Clin Virol"},{"key":"R21-11-20210131","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1128\/JVI.78.9.4628-4637.2004","article-title":"Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).","volume":"78","author":"Lu","year":"2004","journal-title":"J Virol"},{"key":"R22-11-20210131","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1128\/JVI.79.8.4991-4999.2005","article-title":"Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.","volume":"79","author":"Reeves","year":"2005","journal-title":"J Virol"},{"key":"R23-11-20210131","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/QAI.0b013e31817bbc4e","article-title":"Viral dynamics an in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.","volume":"45","author":"Marconi","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-11-20210131","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1097\/QAD.0b013e3282ef1bc8","article-title":"Virological fitness of HIV in patients with resistance to enfuvirtide.","volume":"21","author":"Chibo","year":"2007","journal-title":"AIDS"},{"key":"R25-11-20210131","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/jmv.21138","article-title":"Unexpected dramatic increase in CD4(+) cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.","volume":"80","author":"Soria","year":"2008","journal-title":"J Med Virol"},{"key":"R26-11-20210131","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/jac\/dkl306","article-title":"Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.","volume":"58","author":"Aquaro","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R27-11-20210131","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/QAI.0b013e3181354710","article-title":"Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.","volume":"46","author":"Trabaud","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"pt 4","key":"R28-11-20210131","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1099\/vir.0.80674-0","article-title":"Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.","volume":"86","author":"Locher","year":"2005","journal-title":"J Gen Virol"},{"key":"R29-11-20210131","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/00002030-199308000-00002","article-title":"Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection.","volume":"7","author":"Nielsen","year":"1993","journal-title":"AIDS"},{"key":"R30-11-20210131","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1086\/504693","article-title":"HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.","volume":"194","author":"Melby","year":"2006","journal-title":"J Infect Dis"},{"key":"R31-11-20210131","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/520650","article-title":"Baseline HIV type 1 coreceptor tropism predicts disease progression.","volume":"45","author":"Daar","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200906010-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:55:47Z","timestamp":1786038947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200906010-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181a56f46","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}